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ABSTRACT
In most decision-analytic models in health care, it is assumed that there
is treatment without delay and availability of all required resources.
Therefore, waiting times caused by limited resources and their impact on
treatment effects and costs often remain unconsidered. Queuing theory
enables mathematical analysis and the derivation of several performance
measures of queuing systems. Nevertheless, an analytical approach with
closed formulas is not always possible. Therefore, simulation techniques
are used to evaluate systems that include queuing or waiting, for
example, discrete event simulation. To include queuing in decision-
analytic models requires a basic knowledge of queuing theory and of the
underlying interrelationships. This tutorial introduces queuing theory.
Analysts and decision-makers get an understanding of queue character-
istics, modeling features, and its strength. Conceptual issues are covered,
but the emphasis is on practical issues like modeling the arrival of
patients. The treatment of coronary artery disease with percutaneous
coronary intervention including stent placement serves as an illustrative
queuing example. Discrete event simulation is applied to explicitly model
resource capacities, to incorporate waiting lines and queues in the
decision-analytic modeling example..
Keywords: discrete event simulation, modeling, queue, waiting time.
Introduction
Waiting times in health care have become a major political topic.
Waiting times can lead to poor health status and a reduced
treatment success. Strategies to reduce waiting times for surgery
have been implemented successfully, for example, in Australia, in
New Zealand, and in England [1]. Nevertheless, before a strategy
is implemented, the impact should be analyzed. Queuing theory
could support this analysis [2].
Providers of pharmaceuticals and medical devices are forced
to demonstrate health beneﬁts, safety, and effectiveness of new
developments. In economic evaluations that compare treatment
alternatives (e.g., cost-effectiveness analysis), waiting or queuing
is often not considered in detail. Therefore, results of such evalu-
ations can be biased and might not provide proper information
for health-care providers.
In health care, computer simulation supports analyzing treat-
ment scenarios and patient ﬂows. Discrete event simulation
(DES) offers a wide range of useful characteristics. Disease pro-
gression or remission can be captured, and long-term illnesses or
complex chronic diseases can be modeled. Patients can be
modeled as individuals with speciﬁc characteristics (e.g., age, sex,
severity of disease) [3]. These characteristics inﬂuence the treat-
ment process and the ﬂow of the patient through the model. A
main advantage of DES compared to Markov state-transition
models is that resource constraints can be naturally incorporated
in the model. DES allows modeling of waiting lists or queues and
resource use, waiting time and costs are provided [4–8].
Appropriate queue modeling requires knowledge of charac-
teristics and mechanisms of queuing systems. To support the
conceptualization of economic evaluation that includes limited
capacities and waiting lines, this tutorial article provides an
introduction to queuing. The focus is on modeling aspects and
performance measures using DES.
First, the queue modeling example (treatment of coronary
artery disease (CAD)) is introduced. Thereafter, an introduction
to queuing theory and attributes of queues are given. Data
sources, modeling of arrival, and performance measures are dis-
cussed. Finally, methods and results of the CAD modeling
example are presented.
Example of Queue Model for Treatment
of CAD
“CAD is a condition caused by a narrowing or occlusion of
coronary arteries” [9]. Main treatment interventions are percu-
taneous coronary intervention (PCI) with stent placement and
coronary artery bypass graft (CABG). PCI involves the inﬂation
of a balloon catheter to widen the narrowed artery. To decrease
the risk of restenosis (reocclusion), a mesh tube (stent) is used.
With bare-metal stents (B), the risk of restenosis may still be more
than 30% [10]. Newly developed drug-eluting stents (D) have
shown promising results leading to a decreasing number of
repeated interventions.
In a real-world health-care setting, the existing facilities, staff,
etc., determine the possible number of percutaneous interven-
tions. Interventions are delayed if the demand exceeds the treat-
ment capacity. Subsequently, waiting lists are built up. While
patients are waiting, they receive additional treatment. Waiting
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patients are assumed to suffer from angina symptoms and dis-
tressing uncertainty. An increasing number of restenosis leads to
an increased number of repeated interventions. Consequently, if
the new device reduces the number of repeated interventions, it
could show a positive effect on waiting lists, costs, and health
outcomes (e.g., quality of life).
In the model, new patients (A1) that are referred to PCI and
patients requiring a repeated intervention (A2) are scheduled for
stent implantation [11]. Treatment is provided on the day of
arrival, if treatment capacity is available. Otherwise, patients
may wait and move to a queue (or waiting list). If treatment is
not successful, patients are either sent to be scheduled for stent-
ing again (second-line treatment, A2) or to the surgery depart-
ment for CABG (third-line treatment). CABG is assumed to be
the ﬁnal intervention.
Queue Modeling and QueuingTheory
Queuing models are widely used in service facilities, production,
and material-handling systems, and in general situations where
congestion or competition of scarce resources can occur [12].
Applications in health care ranges from appointment systems to
pharmacokinetics [13].
Attributes of a Queuing System
Generally, a queuing system is described by deﬁning its popula-
tion, the nature of arrival, the service time and mechanism,
queuing behavior, and the queuing discipline.
The population in the stent example (Fig. 1) comprises all
people that are referred to PCI. Therefore, patients for ﬁrst-line
treatment (stent placement) and patients for repeated interven-
tion are considered.
Patients arrive at random for ﬁrst-line stent treatment
depending on the distribution of the risk factors (e.g., diabetes) in
the population. The arrival of patients for second-line treatment
depends on ﬁrst-line treatment. In other settings, arrival might be
deterministic (e.g., scheduled patients at a dentist).
Queue behavior refers to the actions of patients while they are
queuing (or on a waiting list). They might leave the queue
because of a sudden adverse event (myocardial infarction). Long
waiting lists might encourage patients to search for treatment
alternatives. Therefore, they do not enter the queue. In the stent
example, patients enter the queue and wait until treatment
capacities are available and stent placement is done.
Queuing discipline determines the order of treated patients
(prioritization). The stent placement is assumed to be a “ﬁrst-
come, ﬁrst-served” order synonymous to a waiting list that is
processed from the top to the bottom. Newly arriving patients
are included at the bottom of the list. This simpliﬁcation does not
always reﬂect health-care practice pattern. Therefore, queuing
discipline could in addition reﬂect urgent needs (e.g., unstable
patients waiting) or a severity score could determine the order of
patients.
The server refers to any resource or set of resources which are
necessary for the treatment (e.g., staff, devices, medical units).
Service time may be constant or random, depending on patient
characteristic or learning curves. The service mechanism
describes how the service is provided. It is assumed that stent
treatment is provided to a predeﬁned daily number of patients at
the cardiology unit.
Kendall’s notation is a standard to describe and classify
queuing models by arrival process/service process/number of
servers (see Appendix).
Patient Population and the Arrival Process
Data source. How can the population, that is, patients for stent
treatment, be described? Where can we get information about the
size and arriving patterns of the patients in the model?
The patient population can be described from different per-
spectives: need, demand, and provision of treatment. Need is
deﬁned by a body of professionals. Demand describes what pro-
spective patients want, depending on personal (income) and insti-
tutional (price, access) characteristics. Provision describes the
way resources are provided or organized [14]. These perspectives
are not independent. They provide a classiﬁcation of sources
from which estimates for model inputs can be derived.
Need can be derived from epidemiology-based statistics (inci-
dence and prevalence). Nevertheless, incidence and prevalence
are not always directly related to the number of patients who
need and seek treatment. The ability to detect diseases, for
example, inﬂuences these parameters. The evaluation of demand
is relatively complex because of the strong inﬂuence of the pro-
vision of health services and the need. Waiting lists are a way of
rationing that may discourage demand. High demand might lead
to increased provision. Databases of hospital appointments or
accounting systems of health insurance agencies provide retro-
spective information about provision and utilization of the pro-
vided resources, which is an indication of demand and need.
The numbers of patients for ﬁrst-line treatment in the stent
model are derived from the Austrian Cardiac Care registry [15].
Revascularization rates and number of repeated interventions are
based on the CARDIACCESS database (Cardiac Care Network
of Ontario [CNN], Toronto, Canada) [16].
Arrival process. Frequently, a Poisson process is used to model
the arrival of a patient at a discrete point in time [17–19]. The
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Figure 1 Example: patient ﬂow of coronary artery disease (CAD) treatment
including waiting line. CABG, coronary artery bypass graft; PCI, percutaneous
coronary intervention.
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Poisson process assumes that 1) the number of patients who seek
treatment on 1 day is independent from the number the following
day; and 2) the number of arrivals in any time interval only
depends on the length of the interval and not on its starting point.
This means that there is no rush or slack period. Further back-
ground of this important stochastic process is presented in the
Appendix and [29,30].
Performance Measures
Performance measures of queue models are for example utiliza-
tion, waiting time, or number of waiting people (averaged over a
speciﬁc period or current). Utilization denotes the percentage of
time the server or the clinical unit is busy. Queuing theory pro-
vides an analytic approach to estimate long-term performance.
Estimates of further performance measures require assumptions
on arrival and service time distributions. Examples that can be
solved by an analytic approach (i.e., closed formulas) are given in
the Appendix. Nevertheless, as systems become more complex,
simulation is used instead of this analytic approach. For compu-
tational background, see Appendix.
Simulation of Queue Model for CAD and
Stent Treatment
Methods
Figure 1 displays the assumed path of the patients. Two arrival
streams are pooled (A1-new cases, A2-repeated intervention/
second-line treatment). A2 depends on A1.
The arrival of new patients is assumed to be a Poisson process
and daily arrival is modeled with rate l = 14,600/365 [15]. To
account for higher risk of revascularization, the patient cohort is
assumed to be split into four mutually exclusive subgroups: (S1)
nondiabetics with long lesions or narrow vessels; (S2) nondiabet-
ics with short lesions and wide vessels; (S3) diabetics with long
lesions or narrow vessels; and (S4) diabetics with short lesions
and wide vessels. In the simulation, patients are “created” and
randomly assigned to these subgroups Si,i = 1,2,3,4(P1 = 0.38,
P2 = 0.4, P3 = 0.12, P4 = 0.10[16].
It is assumed that restenosis occurs at any time within 1 year
at constant rates (Table 1). The rate of repeated interventions/
number of second-line treatments depends on the provided type
of the stent and on the patient-speciﬁc risk factors (according to
subgroup).
Treatment (D or B) can differ for subgroups. Treatment allo-
cation scenarios describe the allocation of all patient subgroups
to the two treatment alternatives. Each subgroup is assumed to
receive either D or B for ﬁrst- and second-line treatment. CABG
is the third line and ﬁnal intervention if patients still face renar-
rowing. The allocation scenario is deﬁned as = {Stent type for
subgroup (S1), (S2), (S3), (S4)}. In the scenario {DBDD}, for
example, subgroup (S2) receives B and (S1), (S3), (S4) receive D
(Table 2). Patients from all subgroups line up for stenting in the
cardiology unit. In the analysis of treatment outcomes, different
scenarios are evaluated and the impact of stent alternatives (dif-
ferent arrival A2) is analyzed.
The analysis consists of two parts. The base case analysis
assumes immediate treatment. This implies unlimited capacities
for stent interventions. Utilization of the cardiology labs is mea-
sured in four scenarios. Treatment cost and quality of life utility
values are calculated.
In the second part of the analysis, limited capacities for stent-
ing are assumed (38, 40, 42 patients per day). If patients arrive
and the system capacity is reached, they are put on the waiting
list. While they are waiting, they receive drug treatment which
leads to additional costs. Pain and uncertainty lead to a reduced
quality of life. The improvements of drug-eluting stents are
derived from a broader perspective. Besides the direct effect on
patients, also the beneﬁt for patients who subsequently could be
treated earlier (because of less patients waiting for treatment in
total) are estimated. The DES model is built by using ARENA
(Rockwell Software, Inc., Wexford, PA).
Results
Utilization estimates (Fig. 2) indicate that drug-eluting stents
reduce long-term utilization of the cardiology labs. Long-term
average costs (Table 3) indicate a trade-off between the reduction
in utilization and increased average costs per patients for the new
stent device.
Average patient costs under the assumption of limited capaci-
ties are also presented in Table 3. Quality of life utility values are
presented in Table 4 and the incremental cost-effectiveness ratio
is given in Table 5. Figure 3 displays the average waiting time per
patient.
With decreasing resource capacities, the waiting time and the
number of waiting patients increase. Costs increase with decreas-
ing capacities because of additional drugs. Under speciﬁc circum-
stances, this leads to substantial differences in the outcomes of
the treatment alternatives. For example, a resource capacity of 38
stented patients per day is assumed. Hence, the treatment alter-
native DBDB and DBDD not only do imply reduced waiting lists
compared with BBBB, but also do they lead to less or equal
average patient costs.
Discussion
This article provides a tutorial on the application of queue mod-
eling for decision analytic models in health care. Queue modeling
and optimizing are discussed to a broad extent for industrial
applications. The challenging task is to transfer concepts and
ideas to the health-care sector. Patients are not widgets. Factory
workﬂow differs from patient pathways with respect to the com-
Table 1 Summary of model input
Drug-eluting
stent
Bare-metal
stent
Coronary
artery bypass
graft
Revascularization sate in
subgroup [16]
(S1) 0.054 0.095
(S2) 0.054 0.051
(S3) 0.069 0.143
(S4) 0.051 0.055
Resource utilization*
Cost of intervention (EUR) 2,648 1,953 6,560
Cost of hospital stay (EUR) 2,808 2,808 16,180
Time of hospital stay (days) 4.9 4.9 15.2
Cost while waiting (per day
EUR)†
15 15 n.a.
No. of stents per intervention 1.24 1.24 n.a.
Quality of life utility values
(EQ-5D utilities) [28]
Baseline 0.69 0.69 0.68
1 month 0.84 0.84 0.78
6 months 0.86 0.86 0.86
12 months 0.86 0.86 0.87
*Average per patient, Accounting System, Innsbruck Medical University Hospital, unpub-
lished report.
†Expert opinion Division of Cardiology, Medical University Innsbruck,Austria.
Note: During waiting time utility values assumed to be equal to baseline.
n.a., not applicable.
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plexities of treatment success and clinicians’ decisions. Quality of
life is a patient-relevant outcome used in economic evaluations.
Data of quality of life in situations where medical procedures are
delayed are insufﬁcient.
The assumption of capacities (supplies) that are unequal to
the current need is very sensitive from an ethical and political
perspective. Nevertheless, a simulation model provides an ideal
environment to render (hidden) costs and health consequences
and to test alternatives and their impact on resource utilization.
They can identify bottlenecks and help optimize patient ﬂows or
test prioritization rules for speciﬁc patient groups. DES models
have been applied to optimize the performance of clinics with
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Figure 2 Utilization of the cardiology depart-
ment in the coronary artery disease example.
Table 2 Example treatment allocation scenario DBDD
Patient cohort consists of subgroups (deﬁned by baseline risk factors)
Treatment
First Second* Third
(S1) nondiabetes long lesion or narrow vessel 38% D D CABG
(S2) nondiabetes short lesion and wide vessel 40% B B CABG
(S3) diabetes long lesion or narrow vessel 12% D D CABG
(S4) diabetes Short lesion and wide vessel 10% D D CABG
*Type of stent for ﬁrst line assumed to be type of stent for second-line treatment.
B, bare-metal stents; CABG, coronary artery bypass graft; D, drug-eluting stents; DBDD, subgroup (S2) receives B and (S1), (S3), (S4) receive D.
Table 3 Cost per patient (EUR) (CAD example)
Cost per patient (EUR) BBBB BBDB DBDB DBDD
No scarcity
Mean 5269 5285 5446 5516
95% Cl upper bound 5271 5287 5447 5518
95% Cl lower bound 5268 5283 5444 5515
42 patients daily stented
Mean 5457 5420 5491 5561
95% Cl upper bound 5466 5429 5496 5566
95% Cl lower bound 5448 5411 5486 5556
40 patients daily stented
Mean 5950 5894 5922 5988
95% Cl upper bound 5963 5905 5932 5999
95% Cl lower bound 5938 5882 5911 5978
38 patients daily stented
Mean 6585 6519 6532 6600
95% Cl upper bound 6599 6533 6545 6613
95% Cl lower bound 6571 6506 6519 6587
B, bare-metal stents; D, drug-eluting stents; BBBB, subgroup (S1), (S2), (S3), (S4) receive B;
BBDB subgroup (S3) receives D and (S1), (S3), (S4) receive B; CI, conﬁdence interval; DBDB
subgroup (S1), (S3) receives D and (S2), (S4) receive B; DBDD, subgroup (S2) receives
bare-metal stents and (S1), (S3), (S4) receive drug-eluting stents.
Table 4 Average quality of life utility value (CAD example)
Quality of life utility values BBBB BBDB DBDB DBDD
No scarcity
Mean 0.86296 0.86302 0.86311 0.86312
95% Cl upper bound 0.86296 0.86301 0.86311 0.86311
95% Cl lower bound 0.86296 0.86302 0.86311 0.86312
42 patients daily stented
Mean 0.86089 0.86153 0.86262 0.86262
95% Cl upper bound 0.86080 0.86143 0.86257 0.86257
95% Cl lower bound 0.86099 0.86162 0.86267 0.86267
40 patients daily stented
Mean 0.85551 0.85635 0.85790 0.85795
95% Cl upper bound 0.85538 0.85622 0.85779 0.85784
95% Cl lower bound 0.85564 0.85647 0.85802 0.85807
38 patients daily stented
Mean 0.84855 0.84948 0.85120 0.85124
95% Cl upper bound 0.84841 0.84934 0.85106 0.85110
95% Cl lower bound 0.84869 0.84963 0.85135 0.85138
B, bare-metal stents; D, drug-eluting stents; BBBB, subgroup (S1), (S2), (S3), (S4) receive B;
BBDB subgroup (S3) receives D and (S1), (S3), (S4) receive B; CI, conﬁdence interval; DBDB
subgroup (S1), (S3) receives D and (S2), (S4) receive B; DBDD, subgroup (S2) receives
bare-metal stents and (S1), (S3), (S4) receive drug-eluting stents.
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regard to access to care and ﬁnancial viability [20], to analyze
surgical sequencing rules [21], to optimize organ allocation pro-
cesses [22], and to evaluate treatment of cardiac disease [23,24].
The modeling example of CAD treatment points out the
importance of queue modeling for economic evaluation of treat-
ment alternatives. The treatment scenarios differ in waiting times
and consequently show differences in the absolute and relative
cost outcomes. In addition, limited resources inﬂuence quality of
life utility values.
The example yields for improvements. Revascularization
rates could account for time dependencies (e.g., for bare-metal
stents higher in the ﬁrst 3–6 months). Furthermore, long-term
trends and seasonal effects can lead to time dependent arrival
rates. Therefore, generalized nonstationary Poisson Processes
could be applied [22,25,26].
The arrival process of patients is a substantial queuing char-
acteristic. Underlying assumptions, such as incidence or preva-
lence, can be regionally speciﬁc. Therefore, the transferability of
results is limited. Models should be built with the necessary
ﬂexibility to adapt input values and to incorporate expected
long-term trends which inﬂuence arrival (e.g., aging society).
The teaching example follows a simpliﬁed queuing discipline
(ﬁrst come–ﬁrst serve). It does not reﬂect urgent need of unstable
PCI patients. Serious adverse events resulting from delays remain
unconsidered. The analysis does not consider drug-eluting stents
to be the second-line treatment if bare-metal stents are not
successful.
Decision-analytic modeling supports decision-makers in
many ﬁelds of health care [27]. DES is very suitable for simu-
lation of queue models, which is shown by the wide use for
optimizing service systems, production lines, or hospital units.
Nevertheless, such detailed decision-analytic models in health
care require information that might not be collected yet in clini-
cal trials or databases (e.g., prioritization rules and queue dis-
cipline). DES allows for modeling of individuals and interaction
of individuals. An alternative individual-based modeling tech-
nique with the focus on behavioral factors is agent-based mod-
eling. This approach could be considered for the evaluation of
infectious diseases. Decisions on simple queuing problems
might be evaluated using an analytic approach to estimate long-
term results. A Markov Model cohort simulation does not
Table 5 Incremental cost-effectiveness ratio (CAD example)
Max. no. of daily
stented patients
Incremental cost-effectiveness
Cost [EUR]/quality of life utility values
BBBB-BBDB BBBB-DBDB BBBB-DBDD
No limit 275,939 1,143,679 1,580,492
42 Dominated 19,749 60,527
40 Dominated Dominated 15,557
38 Dominated Dominated 5,587
36 Dominated Dominated Dominated
B, bare-metal stents; D, drug-eluting stents; BBBB, subgroup (S1), (S2), (S3), (S4) receive B;
BBDB subgroup (S3) receives D and (S1), (S3), (S4) receive B; DBDB subgroup (S1), (S3)
receives D and (S2), (S4) receive B;DBDD, subgroup (S2) receives bare-metal stents and (S1),
(S3), (S4) receive drug-eluting stents.
DBDD_38
DBDB_38
BBDB_38
BBBB_38
DBDD_40
DBDB_40
BBDB_40
BBBB_40
DBDD_42
DBDB_42
BBDB_42
BBBB_42
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Figure 3 Waiting time of patients (coronary artery disease example).
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allow for dynamic queues. In addition, a state transition
microsimulation with ﬁxed time cycles appears to be not suit-
able (e.g., with respect to ﬂexible arrival and service time
distribution).
Conclusions
The validity of the results of economic evaluation can be
improved by explicitly taking queues into account. Queuing
models should be applied when a substantial difference in
resource utilization is expected between the compared health-
care interventions.
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